PASADENA, Calif.--(BUSINESS WIRE)--Osmetech plc, a molecular diagnostics company, (LSE:OMH - News) (proposed NASDAQ Global Market Symbol: OSMH) today announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of 5,500,000 American Depositary Shares (“ADSs”) (representing 192,500,000 ordinary shares) and listing of such ADSs on the NASDAQ Global Market through a Level III American Depositary Receipt program. The Company’s ordinary shares are currently admitted to trading on the AIM Market of the London Stock Exchange plc (the “AIM Market”) under the ticker symbol “OMH.”
Lazard Capital Markets LLC is acting as sole bookrunner in respect of the offering and Canaccord Adams is acting as co-lead manager. Canaccord Adams has also been engaged as nominated adviser and broker for the purposes of the rules and regulations of the AIM Market. Osmetech has appointed The Bank of New York Mellon as the depositary bank for this offering of ADSs. Any public offering of securities to be made in the United States will be made by means of a prospectus and will contain detailed information about the company and its management, as well as financial statements. Copies of the preliminary prospectus related to the offering may be obtained, when available, from Lazard Capital Markets LLC, Attn: Syndicate Department, 30 Rockefeller Plaza, New York, New York 10020 or by phone at 212-632-6717, and from Canaccord Adams, Attn: Syndicate Department, 99 High Street, 12th Floor, Boston, MA 02110 or by email at email@example.com.
A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Osmetech plc
Osmetech plc is an international diagnostics business with operations in Boston and Pasadena in the US, serving the molecular diagnostic market targeting hospitals and reference laboratories. Osmetech has rights to a portfolio of over 200 issued and pending patents and has launched its first generation eSensor 4800 platform, an electrochemistry-based array system, together with an FDA cleared in vitro diagnostic test for Cystic Fibrosis carrier detection. In July 2008, Osmetech received FDA clearance for its second generation eSensor XT-8 molecular diagnostics platform and Warfarin Sensitivity Test.
James N. White
Source: Osmetech plc